Webcast: How Will Oral Cladribine and FTY-720 Impact the Multiple Sclerosis Market?

Time & Location

Originally Presented: October 7, 2009 10:00 AM, Webcast

Presenter(s):

GLG Expert Contributor

Agenda:

  • How receptive are surveyed neurologists and MCOs to oral cladribine and FTY-720? How will the efficacy and safety profiles of these drugs influence surveyed neurologists’ prescribing decisions and surveyed MCOs’ reimbursement decisions for the two agents?
  • To which patient populations will oral cladribine and FTY-720 be prescribed and in what line of therapy will they be used? How will their patterns of use affect their commercial potential?
  • What impact will the emergence of oral cladribine and FTY-720 have on currently-marketed MS drugs?
  • Do surveyed MCOs expect to include oral cladribine and FTY-720 on their formularies and on what formulary tiers do they expect to place these agents?
  • What restrictions will MCOs place on oral cladribine and FTY-720 and how will the extent of formulary coverage of each agent affect its commercial prospects?

View Webcasts & Teleconferences in Healthcare

View All Webcasts & Teleconferences in Healthcare

About GLG Live Meetings

A program focused on educating business and investment professionals through seminars on current trends and core concepts in various industries. Detailed workbooks distributed at the Seminars provide educational reference materials for later review. GLG Live Meetings enable clients to increase thier own industry education by proposing new seminar topics or adding agenda terms to currently scheduled seminars.